Hm Payson & CO Amgen Inc Transaction History

Hm Payson & CO

$5.81 Billion
Q3 2024

A detailed history of Hm Payson & CO transactions in Amgen Inc stock. As of the latest transaction made, Hm Payson & CO holds 199,180 shares of AMGN stock, worth $52.2 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares

199,180

Previous 202,113 1.45%

Holding current value

$52.2 Million

Previous $63.2 Million 1.63%

% of portfolio

1.1%

Previous 1.15%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$309.38 - $337.38 $907,411 - $989,535	-2,933 Reduced 1.45%	199,180 $64.2 Million
Q2 2024 Aug 13, 2024	BUY	$262.75 - $319.31 $7.78 Million - $9.45 Million	29,602 Added 17.16%	202,113 $63.2 Million
Q1 2024 Jun 20, 2024	BUY	$268.87 - $324.56 $8.36 Million - $10.1 Million	31,081 Added 21.98%	172,511 $49 Million
Q4 2023 Feb 13, 2024	BUY	$255.7 - $288.46 $3.93 Million - $4.44 Million	15,388 Added 12.21%	141,430 $40.7 Million
Q3 2023 Nov 06, 2023	BUY	$218.65 - $271.46 $572,644 - $710,953	2,619 Added 2.12%	126,042 $33.9 Million
Q2 2023 Jul 17, 2023	BUY	$214.27 - $253.37 $838,009 - $990,930	3,911 Added 3.27%	123,423 $27.4 Million
Q1 2023 Apr 18, 2023	BUY	$225.79 - $275.2 $1.3 Million - $1.58 Million	5,751 Added 5.06%	119,512 $28.9 Million
Q4 2022 Feb 06, 2023	SELL	$229.03 - $291.01 $3.2 Million - $4.07 Million	-13,974 Reduced 10.94%	113,761 $29.9 Million
Q3 2022 Oct 25, 2022	BUY	$224.46 - $253.15 $2 Million - $2.26 Million	8,921 Added 7.51%	127,735 $28.8 Million
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $702,973 - $782,286	3,047 Added 2.63%	118,814 $28.9 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $1.45 Million - $1.61 Million	6,634 Added 6.08%	115,767 $28 Million
Q4 2021 Feb 15, 2022	SELL	$198.88 - $227.6 $30.5 Million - $34.9 Million	-153,286 Reduced 58.41%	109,133 $24.6 Million
Q3 2021 Nov 30, 2021	SELL	$212.27 - $248.7 $6.1 Million - $7.15 Million	-28,749 Reduced 9.87%	262,419 $55.8 Million
Q2 2021 Aug 17, 2021	BUY	$233.58 - $259.14 $4.47 Million - $4.96 Million	19,135 Added 7.03%	291,168 $71 Million
Q1 2021 Jun 15, 2021	BUY	$221.91 - $258.6 $1.07 Million - $1.25 Million	4,834 Added 1.81%	272,033 $67.7 Million
Q4 2020 Mar 10, 2021	BUY	$216.38 - $257.67 $398,139 - $474,112	1,840 Added 0.69%	267,199 $61.4 Million
Q3 2020 Dec 21, 2020	BUY	$234.65 - $260.95 $1.13 Million - $1.25 Million	4,799 Added 1.84%	265,359 $67.4 Million
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $520,438 - $638,648	2,631 Added 1.02%	260,560 $61.5 Million
Q1 2020 Jul 01, 2020	BUY	$182.24 - $241.7 $1.78 Million - $2.36 Million	9,783 Added 3.94%	257,929 $52.3 Million
Q4 2019 Feb 18, 2020	BUY	$189.21 - $243.2 $890,043 - $1.14 Million	4,704 Added 1.93%	248,146 $59.8 Million
Q3 2019 Nov 12, 2019	BUY	$174.11 - $208.62 $1.29 Million - $1.55 Million	7,418 Added 3.14%	243,442 $47.1 Million
Q2 2019 Aug 15, 2019	BUY	$166.7 - $195.41 $300,560 - $352,324	1,803 Added 0.77%	236,024 $43.5 Million
Q1 2019 Jul 31, 2019	BUY	$180.87 - $203.88 $41.7 Million - $47 Million	230,595 Added 6359.49%	234,221 $44.5 Million
Q4 2018 Feb 15, 2019	SELL	$178.4 - $208.25 $28.2 Million - $32.9 Million	-158,116 Reduced 97.76%	3,626 $706,000
Q3 2018 Nov 30, 2018	BUY	$185.29 - $208.89 $30 Million - $33.8 Million	161,742 New	161,742 $33.5 Million
Q2 2018 Aug 27, 2018	SELL	$166.05 - $186.51 $35.2 Million - $39.5 Million	-211,760 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$169.43 - $198.0 $3.26 Million - $3.8 Million	19,215 Added 9.98%	211,760 $36.1 Million
Q4 2017 Feb 16, 2018	BUY	$168.79 - $188.59 $1.44 Million - $1.61 Million	8,539 Added 4.64%	192,545 $33.5 Million
Q3 2017 Nov 06, 2017	BUY	$167.29 - $191.0 $30.8 Million - $35.1 Million	184,006	184,006 $34.3 Million

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

407M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.

Account